Value proposition

Building a pipeline of immuno-infectiology candidates to fight against anti-microbial resistance

Alpioner Therapeutics is a biotech company developing a whole-cell vaccine platform consisting of genetically optimized strains of human pathogens undergoing an attenuation process which delivers a Killed but Metabolically Active (KBMA) vaccine substance. This platform has already generated a first candidate targeting a human multi-resistant pathogen, Pseudomonas aeruginosa. It carries on the potential for further applications against other resistant pathogens.
Alpioner Therapeutics mission is to build a pipeline of immuno-infectiology candidates to fight against anti-microbial resistance (AMR).